Leonardo Olivera

  • Current company LEONARDO OLIVERA
  • Location Uruguay

Clausen focuses is on the commercialization of high-cost and highly specialized biological and biotechnology products. Clausen’s R&D strength for the past six years has been the development of a molecule – Human Recombinant Thrombopoietin, TPO – which will potentially be used in the treatment of cancer. TPO is the first molecule entirely developed in Uruguay – its patent was granted in Uruguay in 2002 – and it is by far Uruguay’s most sophisticated and ambitious genetic engineering project. Leonardo was selected as an Endeavor entrepreneur in 2002.

Stay up to date on our entrepreneurs, events, research and more.